ReviewEuropean journal of pain (London, England)2026
Lesion Without Pain, Pain Without Certainty: A Critical Reappraisal of the NeuPSIG Diagnostic Algorithm for Neuropathic Pain.
Review in European journal of pain (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe NeuPSIG diagnostic algorithm is regarded as the reference framework for the diagnosis of neuropathic pain. It is based on a hierarchical model in which diagnostic certainty increases with the presumed objectivity of the evidence, progressing from patient-reported symptoms to clinical examination and, ultimately, to confirmatory tests demonstrating a neurological lesion.
methodsIn this position paper, we critically examine the conceptual foundations of this framework. We argue that the distinction between subjective and objective evidence is less clear-cut than assumed, as so-called objective biomarkers are themselves influenced by patient-related, examiner-dependent and methodological factors. Moreover, the identification of a neurological lesion does not establish a causal relationship with pain, raising fundamental questions about the validity of using lesion-based markers as surrogates for pain classification.
resultsDrawing on evidence from bedside examination, quantitative sensory testing, neurophysiology and structural biomarkers, we highlight the limitations of the current hierarchical approach. We show that clinical reasoning in neuropathic pain does not follow a linear progression from subjective to objective data, but rather relies on the integration of multiple, context-dependent sources of information.
conclusionWe propose an alternative framework based on converging evidence, in which patient history, pain characteristics and clinical examination are accorded equivalent weight, and diagnostic confidence emerges from their coherence rather than from a hierarchy of objectivity. Within this model, investigations aimed at identifying a neurological lesion are repositioned as tools for aetiological clarification rather than as determinants of pain classification. In our opinion, this approach offers a more conceptually coherent and clinically relevant framework for the diagnosis of neuropathic pain. SIGNIFICANCE STATEMENT: While the NeuPSIG algorithm has been useful to standardize the diagnosis of neuropathic pain in the research setting, this algorithm is based on a hierarchical model in which objective measures (sensory deficits, complementary investigations) largely outweigh self-reported symptoms. We challenge this assumption by showing that 'objective' measures are also prone to variability and propose a model which gives equivalent weight to patient reported outcomes. This model may offer a more clinically relevant approach to the diagnosis of neuropathic pain.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.